JAK Inhibitors for Myelofibrosis: Strengths and Limitations.

IF 2.7 3区医学 Q2 HEMATOLOGY Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-10-14 DOI:10.1007/s11899-024-00744-9

K Thaw, C N Harrison, P Sriskandarajah

{"title":"JAK Inhibitors for Myelofibrosis: Strengths and Limitations.","authors":"K Thaw, C N Harrison, P Sriskandarajah","doi":"10.1007/s11899-024-00744-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge. In this review we critically analyze the strengths and limitations of currently available JAK inhibitors.Recent findings: In MF patients, JAK inhibitors have been associated with reduced symptom burden and spleen size, as well as improved survival. However, durability of response and development of treatment resistance remain an issue. Recently, there has been increased efforts to optimize treatment with the development of highly selective JAK inhibitors, as well as use of combination agents to counter disease resistance through targeting aberrant signaling pathways. Treatment of MF patients with JAKi therapy can be challenging but the development of more potent and selective JAK inhibitors, as well as combination therapies, represent exciting treatment advances in this field.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"264-275"},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567979/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11899-024-00744-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge. In this review we critically analyze the strengths and limitations of currently available JAK inhibitors.

Recent findings: In MF patients, JAK inhibitors have been associated with reduced symptom burden and spleen size, as well as improved survival. However, durability of response and development of treatment resistance remain an issue. Recently, there has been increased efforts to optimize treatment with the development of highly selective JAK inhibitors, as well as use of combination agents to counter disease resistance through targeting aberrant signaling pathways. Treatment of MF patients with JAKi therapy can be challenging but the development of more potent and selective JAK inhibitors, as well as combination therapies, represent exciting treatment advances in this field.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗骨髓纤维化的 JAK 抑制剂：优势与局限。

综述的目的：自发现 JAK2 V617F 基因突变和随后开发出 JAK 抑制剂（JAKis）以来，骨髓纤维化（MF）的情况发生了变化。然而，JAKis的治疗仍然是一项挑战。在这篇综述中，我们认真分析了目前可用的JAK抑制剂的优势和局限性：在中风患者中，JAK抑制剂与减轻症状负担、缩小脾脏以及改善生存率有关。然而，反应的持久性和耐药性的产生仍是一个问题。最近，随着高选择性 JAK 抑制剂的开发，以及通过靶向异常信号通路使用联合药物来对抗耐药性，人们越来越努力优化治疗。用JAKi疗法治疗MF患者可能具有挑战性，但开发出更强效、更具选择性的JAK抑制剂以及联合疗法，代表着这一领域令人振奋的治疗进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.